<DOC>
	<DOCNO>NCT00608894</DOCNO>
	<brief_summary>An open-label , multi-center , prospective , randomize study evaluate efficacy , safety tolerability LCP-Tacro tablet give daily vs. azathioprine , combination prednisone , treatment autoimmune hepatitis ( AIH ) .</brief_summary>
	<brief_title>LCP-Tacro vs. Azathioprine Treatment Autoimmune Hepatitis</brief_title>
	<detailed_description>An open-label , multi-center , prospective , randomize study evaluate efficacy , safety tolerability LCP-Tacro tablet give daily vs. azathioprine treatment autoimmune hepatitis ( AIH ) . Patients histologically confirm chronic hepatitis fulfill criterion establish International Autoimmune Hepatitis Group ( IAIHG ) Inclusion Exclusion criterion enrol sign informed consent document . Up 60 patient randomize ( 1:1 ) receive treatment LCP-Tacro + prednisone vs. azathioprine ( AZA ) + prednisone . - LCP-Tacro start 2 mg daily ( q.d . ) weekly measurement tacrolimus whole blood trough level adjustment daily dose LCP-Tacro achieve target tacrolimus level 3 - 6 ng/mL . Patients histological evidence cirrhosis Model End-Stage Liver Disease ( MELD ) score ≤ 8 commence LCP-Tacro fix dose 1 mg daily , subsequent dosage adjustment maintain tacrolimus trough level 3 - 6 ng/mL . - AZA start 50 - 100 mg ( approximately 1 mg/kg ) daily ( q.d. ) . Patients also commence treatment prednisone 30 mg/day one week , 20 mg/day one week , 15 mg/day two week , 10 mg/day Month 6 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Men woman least 18 year age diagnosis definite probable AIH define revise International Autoimmune Hepatitis Group ( IAIHG ) criterion Elevation serum ALT ≥ 1.5 time upper limit normal Liver biopsy show chronic hepatitis consistent AIH Patients able swallow study medication Patients capable understanding purpose risk study , give write informed consent willing participate comply study Women childbearing potential must negative serum pregnancy test within seven day prior receive study medication agree use contraceptive measure avoid pregnancy participation trial . Patients concurrent liver disease Patients cirrhosis liver biopsy MELD score &gt; 15 Patients history presence decompensated liver disease Patients serum creatinine ≥ 1.5 mg/dL prior enrollment Patients positive HCV RNA Hepatitis B surface antigen ( HBsAg ) Patients history alcohol intake &gt; 25 g/day within past six month Patients TSH outside normal range accompany abnormal T4 Patients alphafetoprotein ≥ 20 ng/mL Patients severe anemia ( hemoglobin &lt; 8 g/dL ) , leukopenia ( WBC &lt; 4000/mm3 ) , thrombocytopenia ( platelet count &lt; 100,000/mm3 ) Patients history recent exposure hepatotoxic drug Patients require therapy immunosuppressive agent prescribe study Patients unable unwilling provide inform consent Pregnant nursing woman Patients reproductive potential unwilling/unable use double barrier method contraception Patients treat another investigational agent three month prior enrollment Patients receive drug interfere tacrolimus metabolism Patients current malignancy history malignancy ( within past 5 year ) , except basal nonmetastatic squamous cell carcinoma skin treat successfully Patients uncontrolled concomitant infection , systemic infection require treatment , unstable medical condition could interfere study objective Patients severe diarrhea , vomit , active peptic ulcer gastrointestinal disorder may affect absorption tacrolimus Patients know hypersensitivity azathioprine , corticosteroid tacrolimus Patients form current substance abuse , psychiatric disorder condition , opinion Investigator , may invalidate communication Investigator Patients recipient organ transplant require treatment immunosuppressives corticosteroid disease AIH .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Autoimmune hepatitis</keyword>
	<keyword>Chronic active hepatitis</keyword>
</DOC>